What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

Exlla DS 30ML

Cefpodoxime 50mg

Pack: 30ML
Format: With Carton

MRP₹84.38

A high-potency, third-generation cephalosporin pediatric suspension designed for the effective management of acute bacterial infections. EXLLA DS provides a broad-spectrum bactericidal action that is particularly effective against respiratory, ear, and skin pathogens, ensuring rapid clinical recovery in children.

About The Product

Key Benefits

Advanced Third-Generation Bactericidal Action

Cefpodoxime Proxetil 50mg is an advanced antibiotic that works by inhibiting bacterial cell wall synthesis. As a third-generation cephalosporin, it possesses enhanced stability against many beta-lactamase enzymes, allowing it to destroy a wider range of resistant bacteria compared to older-generation penicillins or cephalosporins.

Broad-Spectrum Clinical Efficacy

EXLLA DS is highly effective against both Gram-positive and Gram-negative organisms. It is a frontline choice for treating common pediatric infections such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*, which are frequently responsible for persistent ear and throat infections.

High Bioavailability and Tissue Penetration

Cefpodoxime is prodrug that is rapidly absorbed and converted into its active form in the body. It achieves high therapeutic concentrations in critical areas such as the tonsils, sinuses, and lung tissues, ensuring that the infection is targeted at its source for faster symptom relief.

Ideal for Switch Therapy

Due to its powerful oral efficacy, EXLLA DS is often used as "step-down" therapy for children who have started treatment with injectable antibiotics. It provides a convenient oral alternative that maintains the same high level of antibacterial cover, allowing the child to complete their recovery comfortably at home.

Double-Strength Pediatric Precision

The "DS" (Double Strength) 50mg/5ml concentration is specifically designed for older children or more severe infections where a higher therapeutic dose is required. This allows for a lower volume of liquid per dose, which is easier for children to consume and helps ensure they finish the full prescribed course.

Excellent Safety and Tolerability

EXLLA DS is formulated to be gentle on the pediatric gastrointestinal tract. It has a lower incidence of stomach upset and diarrhea compared to many other broad-spectrum antibiotics, making it a reliable and well-tolerated option for children with sensitive systems.

Indication Acute Otitis Media (Middle Ear Infection), Pharyngitis and Tonsillitis, Community-Acquired Pneumonia, Acute Sinusitis, Skin and Soft Tissue Infections, Uncomplicated Urinary Tract Infections.

Indications

Acute Otitis Media (Middle Ear Infection)
Pharyngitis and Tonsillitis
Community-Acquired Pneumonia
Acute Sinusitis
Skin and Soft Tissue Infections
Uncomplicated Urinary Tract Infections.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

Exlla DS 30ML